Phibro Animal Health (NASDAQ:PAHC) CEO Sells $50,079.25 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 1,235 shares of Phibro Animal Health stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25. Following the transaction, the chief executive officer owned 15,445 shares of the company’s stock, valued at approximately $626,294.75. The trade was a 7.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total transaction of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total transaction of $141,011.20.

Phibro Animal Health Stock Up 0.1%

Shares of PAHC traded up $0.04 during midday trading on Tuesday, hitting $39.52. The company had a trading volume of 95,621 shares, compared to its average volume of 194,254. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of 23.81, a PEG ratio of 1.10 and a beta of 0.79. The company’s 50 day moving average price is $40.05 and its 200 day moving average price is $37.63.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities research analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is 28.92%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PAHC. Tudor Investment Corp ET AL grew its stake in shares of Phibro Animal Health by 3.4% in the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after acquiring an additional 338 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Phibro Animal Health by 2.9% during the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the period. Farther Finance Advisors LLC raised its position in shares of Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after buying an additional 546 shares during the period. Finally, Prospera Financial Services Inc grew its position in Phibro Animal Health by 3.6% during the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company’s stock worth $508,000 after buying an additional 690 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on PAHC. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. increased their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and an average target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.